Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26674880 | 0.82 | RAB9A (0.72) | FLT3RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL26674898 | 0.82 | FLT3 (0.57) | FLT3RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL26675103 | 0.80 | FLT3 (0.59) | FLT3RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL26891859 | 0.79 | FLT3 (0.55) | FLT3RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL26674900 | 0.79 | RAB9A (0.57) | FLT3RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL26674971 | 0.79 | FLT3 (0.54) | FLT3RAB9ANPC1 | |
| SCHEMBL26674857 | 0.77 | FLT3 (0.60) | FLT3RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL26674842 | 0.75 | RAB9A (0.62) | FLT3RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL1748776 | 0.75 | MAOA (0.42) | FLT3RAB9ANPC1SMN1; SMN2MAOA | |
| SCHEMBL26674949 | 0.74 | FLT3 (0.73) | FLT3RAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617758-B2 | Quinazoline derivative having FLT3 inhibitory activity, and use thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2026-05-05 | — | — | US | claimed |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | claimed |
| WO-2022065894-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | 한양대학교 에리카산학협력단 | 2022-03-31 | — | — | WO | claimed |
| US-12617758-B2 | Quinazoline derivative having FLT3 inhibitory activity, and use thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2026-05-05 | — | — | US | disclosed |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | disclosed |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-11-09 | — | — | US | disclosed |
| WO-2022065894-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | 한양대학교 에리카산학협력단 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617758-B2 | Quinazoline derivative having FLT3 inhibitory activity, and use thereof | FLT3, MCL1, ROS1 | FLT3 1/4885RAB9A 3262/4885NPC1 2713/4885 |
| US-20230357164-A1 | NOVEL QUINAZOLINE DERIVATIVE HAVING FLT3 INHIBITORY ACTIVITY, AND USE THEREOF | FLT3, ABL1, MCL1 | FLT3 1/4885RAB9A 1637/4885NPC1 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.